NO20006113L - Use of cyclosporins in the treatment of inflammatory autoimmune diseases - Google Patents

Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Info

Publication number
NO20006113L
NO20006113L NO20006113A NO20006113A NO20006113L NO 20006113 L NO20006113 L NO 20006113L NO 20006113 A NO20006113 A NO 20006113A NO 20006113 A NO20006113 A NO 20006113A NO 20006113 L NO20006113 L NO 20006113L
Authority
NO
Norway
Prior art keywords
cyclosporins
treatment
autoimmune diseases
inflammatory autoimmune
inflammatory
Prior art date
Application number
NO20006113A
Other languages
Norwegian (no)
Other versions
NO20006113D0 (en
Inventor
Peter Hiestand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20006113D0 publication Critical patent/NO20006113D0/en
Publication of NO20006113L publication Critical patent/NO20006113L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20006113A 1998-06-02 2000-12-01 Use of cyclosporins in the treatment of inflammatory autoimmune diseases NO20006113L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811854.0A GB9811854D0 (en) 1998-06-02 1998-06-02 Organic compounds
PCT/EP1999/003770 WO1999062540A1 (en) 1998-06-02 1999-05-31 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Publications (2)

Publication Number Publication Date
NO20006113D0 NO20006113D0 (en) 2000-12-01
NO20006113L true NO20006113L (en) 2001-01-25

Family

ID=10833083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006113A NO20006113L (en) 1998-06-02 2000-12-01 Use of cyclosporins in the treatment of inflammatory autoimmune diseases

Country Status (17)

Country Link
EP (1) EP1082130A1 (en)
JP (2) JP4523154B2 (en)
KR (1) KR20010043969A (en)
CN (1) CN1304315A (en)
AU (1) AU750422B2 (en)
BR (1) BR9910860A (en)
CA (1) CA2333315A1 (en)
GB (1) GB9811854D0 (en)
HU (1) HUP0102142A3 (en)
ID (1) ID27576A (en)
IL (1) IL139589A0 (en)
NO (1) NO20006113L (en)
PL (1) PL344451A1 (en)
SK (1) SK18142000A3 (en)
TW (2) TWI250021B (en)
WO (1) WO1999062540A1 (en)
ZA (1) ZA200006464B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297217T1 (en) 1999-10-27 2005-06-15 Alexandra Lucas COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION
US7419670B2 (en) * 2000-09-29 2008-09-02 Viron Therapeutics, Inc. Method of treating arthritis with SERP-1 and an immunosuppressant
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007532507A (en) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト Use of cyclosporine for the treatment of cerebral ischemia and brain and spinal cord injury
BRPI0513370A (en) 2004-07-14 2008-05-06 Novartis Ag use of a combination of pegylated cyclosporine and interferon for treatment of hepatitis c (hcv)
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
JP2008514702A (en) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Novel cyclosporine analogues and their pharmaceutical use
ATE490778T1 (en) * 2004-10-01 2010-12-15 Debiopharm Sa USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
NZ555142A (en) * 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
RU2427372C2 (en) 2005-06-17 2011-08-27 Новартис Аг Application of sangliferin for treating hepatitis c virus
JP2007112775A (en) * 2005-10-24 2007-05-10 Hamamatsu Univ School Of Medicine Use of cyclosporines in the treatment of cytomegalovirus infection
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (en) * 2008-06-06 2015-11-24 スシネキス インク Cyclosporine analogues and their use in the treatment of HCV infection
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
CN102869367A (en) * 2009-12-09 2013-01-09 西尼克斯公司 Novel cyclic peptides
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
US20140213508A1 (en) * 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111730B (en) * 1990-11-02 2003-09-15 Novartis Ag Process for the preparation of non-immunosuppressive cyclosporins
AR006514A1 (en) * 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
CZ288631B6 (en) * 1996-01-18 2001-08-15 Galena, A. S. Therapeutic preparations containing cyclosporin
CZ288739B6 (en) * 1996-08-01 2001-08-15 Galena, A. S. Cyclosporin containing medicinal preparations

Also Published As

Publication number Publication date
IL139589A0 (en) 2002-02-10
WO1999062540A1 (en) 1999-12-09
TW200522975A (en) 2005-07-16
HUP0102142A2 (en) 2001-11-28
ID27576A (en) 2001-04-12
ZA200006464B (en) 2002-03-11
JP2002516873A (en) 2002-06-11
JP4523154B2 (en) 2010-08-11
KR20010043969A (en) 2001-05-25
PL344451A1 (en) 2001-11-05
AU4372499A (en) 1999-12-20
TWI250022B (en) 2006-03-01
AU750422B2 (en) 2002-07-18
HUP0102142A3 (en) 2001-12-28
JP2010059177A (en) 2010-03-18
BR9910860A (en) 2001-03-06
NO20006113D0 (en) 2000-12-01
TWI250021B (en) 2006-03-01
SK18142000A3 (en) 2001-06-11
CN1304315A (en) 2001-07-18
CA2333315A1 (en) 1999-12-09
EP1082130A1 (en) 2001-03-14
GB9811854D0 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
NO20006113D0 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
PT1028954E (en) IMIDAZOLES SUBSTITUIDOS UTEIS IN THE TREATMENT OF INFLAMMATORY DISEASES
PT966447E (en) SMALL UTILIZATION MOLECULES IN THE TREATMENT OF INFLAMMATORY DISEASES
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
IL133766A0 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
PL362984A1 (en) Compounds useful in the treatment of inflammatory diseases
DK1047428T3 (en) Use of morpholinol in the treatment of sexual disorders
DE69930165D1 (en) HUMAN DELTA 5 DESATURASE GEN
EE03512B1 (en) Epinastine for use in the treatment of pain
PT946175E (en) USE OF A COMBINATION OF H +, K + -ATPASE AND GLUCOCORTICIOD INHIBITORS IN THE TREATMENT OF NASA POLLS
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO20031525L (en) Chemokine mutants in the treatment of multiple sclerosis
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
EP1027007A4 (en) DENTAL TREATMENT TECHNIQUES
EP1224201A4 (en) 32 PROTEINS SPECIFIED BY PEOPLE
ID30458A (en) OSANETAN IN TREATMENT OF SOUL DISORDERS
NO20010044L (en) Use of texaphyrins in macrophage-mediated diseases
HUP0200354A3 (en) Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
NO20030762L (en) Improved specificity in the treatment of diseases
DK5198A (en) Endoscopic Dormia foreign body extractor
AU2002300624A1 (en) Substituted imidazoles useful in the treatment of inflammatory diseases
IT1311913B1 (en) USE OF 6-METHYLMERCAPTOPURIN RIBOSIDE IN OPHTHALMOLOGICAL COMPOSITIONS.
AU2002306210A1 (en) 2-substituted imidazoles useful in the treatment of inflammatory diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application